MLICM
YMAB

Metropolitan Life Insurance Company (MetLife)’s Y-mAbs Therapeutics YMAB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,055
Closed -$33.4K – 2149
2024
Q1 		$33.4K Hold
2,055
– – ﹤0.01% 1604
2023
Q4 		$14K Hold
2,055
– – ﹤0.01% 2057
2023
Q3 		$11.2K Hold
2,055
– – ﹤0.01% 2163
2023
Q2 		$14K Hold
2,055
– – ﹤0.01% 2116
2023
Q1 		$10.3K Sell
2,055
-238
-10% -$972 ﹤0.01% 2151
2022
Q4 		$11.2K Sell
2,293
-12
-0.5% -$87 ﹤0.01% 2251
2022
Q3 		$33.2K Hold
2,305
– – ﹤0.01% 1736
2022
Q2 		$34.9K Hold
2,305
– – ﹤0.01% 1723
2022
Q1 		$27.4K Sell
2,305
-7,268
-76% -$74.6K ﹤0.01% 1934
2021
Q4 		$155K Hold
9,573
– – ﹤0.01% 2202
2021
Q3 		$273K Buy
9,573
+140
+1% +$4.41K ﹤0.01% 1847
2021
Q2 		$319K Buy
9,433
+472
+5% +$15.2K ﹤0.01% 1812
2021
Q1 		$271K Sell
8,961
-303
-3% -$12.4K ﹤0.01% 1806
2020
Q4 		$459K Hold
9,264
– – 0.01% 1413
2020
Q3 		$356K Hold
9,264
– – 0.01% 1435
2020
Q2 		$400K Buy
9,264
+1,978
+27% +$74.8K 0.01% 1372
2020
Q1 		$190K Hold
7,286
– – ﹤0.01% 1615
2019
Q4 		$228K Hold
7,286
– – ﹤0.01% 1825
2019
Q3 		$190K Buy
7,286
+5,697
+359% +$146K ﹤0.01% 1915
2019
Q2 		$36.3K Buy
+1,589
New +$36.5K ﹤0.01% 2530

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s YMAB Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Y-mAbs Therapeutics (YMAB) in Q2 2024, closing a stake of 2,055 shares — an estimated $33.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in YMAB in Q2 2019 and held it in 20 quarters. The position peaked at $459K in Q4 2020. 96 funds tracked by Wall St. Rank hold YMAB as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Y-mAbs Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,055 Y-mAbs Therapeutics shares in Q2 2024, an estimated $33.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Y-mAbs Therapeutics position peaked at $459K in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.